SI-BONE develops medical devices for sacroiliac (SI) joint dysfunction, a source of chronic lower-back and pelvic pain. Its flagship iFuse implant system is designed for minimally invasive SI joint fusion. The company sells primarily to surgeons and hospitals treating patients who have not found lasting relief from conservative care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 47.3 | — | -6.5 | — |
| Q2 2025 | 48.6 | — | -6.2 | — |
| Q3 2025 | 48.7 | — | -4.6 | — |
| Q4 2025 | 56.4 | — | -1.6 | — |
| Q1 2026 | 52.6 | 11.2% | -4.3 | — |
| Q2 2026 | 56 | 15.2% | -4.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Navient Corporation (NAVI), Apogee Enterprises, Inc. (APOG), Eagle Bancorp, Inc. (EGBN), Forbright, Inc. (FRBT), Aebi Schmidt Holding AG (AEBI), SL Science Holding Limited (SLBT)